RU2018128737A - Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов - Google Patents
Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов Download PDFInfo
- Publication number
- RU2018128737A RU2018128737A RU2018128737A RU2018128737A RU2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A RU 2018128737 A RU2018128737 A RU 2018128737A
- Authority
- RU
- Russia
- Prior art keywords
- imatinib
- acceptable salt
- prevention
- treatment
- pharmaceutically acceptable
- Prior art date
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims 6
- 229960002411 imatinib Drugs 0.000 title claims 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims 6
- 150000003839 salts Chemical class 0.000 title claims 6
- 230000002265 prevention Effects 0.000 title claims 3
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 claims 2
- 208000037312 Familial drusen Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- -1 4-methylpiperazin-1-ylmethyl Chemical group 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000007714 retinoschisis Diseases 0.000 claims 1
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Применение иматиниба (4-(4-метилпиперазин-1-илметил)-N-[4-метил-3-((4-пиридин-3-ил)пиримидин-2-ил-амино)фенил]-бензамид) или его фармацевтически приемлемой соли в качестве агента для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов.
2. Применение по п.1 в качестве приемлемой соли иматиниба иматиниб мезилата.
3. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и 2 для лечения или предупреждений заболевания, связанного с проницаемостью сосудов, выбранного из группы, состоящей из хороидальной неоваскуляризации, пигментного ретинита, связанного с глаукомой, ретролентальной фиброплазии (синдрома Терри), диабетического макулярного отёка, возрастной дегенерации жёлтого пятна, глаукомы, дистрофии роговицы, отслоения сетчатки, Штаргардта дегенерации жёлтого пятна, аутосомных доминантных старческих бляшек, диабетической ретинопатии, дистрофии жёлтого пятна (болезни Беста), цистоидного отёка жёлтого пятна, ишемической ретинопатии, дегенеративного заболевания сетчатки, вызванного воспалением, юношеского, связанного с Х-хромосомой ретиношизиса, Malattia Leventinese (ML), сотовидного хориоидита Дойна, и воспалительных заболеваний, связанных с клетками эндотелия сосудов.
4. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и 2 в дозе от 1 до 20 мг/кг в сутки для лечения или предупреждения диабетической ретинопатии.
5. Применение иматиниба или его фармацевтически приемлемой соли по пп.1 и/или 4 в количестве 0,001 - 50 вес.% для приготовления фармацевтической композиции в пересчёте на ее общий вес.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120065193A KR101386697B1 (ko) | 2012-06-18 | 2012-06-18 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| KR10-2012-0065193 | 2012-06-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014151382A Division RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018128737A3 RU2018128737A3 (ru) | 2019-03-14 |
| RU2018128737A true RU2018128737A (ru) | 2019-03-14 |
Family
ID=49768959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014151382A RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
| RU2018128737A RU2018128737A (ru) | 2012-06-18 | 2013-06-10 | Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014151382A RU2014151382A (ru) | 2012-06-18 | 2013-06-10 | Композиция для лечения или профилактики заболеваний, вызванных расстройствами сосудистой проницаемости, содержащая иматиниб или его фармацевтически приемлемые соли в качестве активного ингредиента |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9511068B2 (ru) |
| EP (1) | EP2862573B1 (ru) |
| JP (1) | JP6030234B2 (ru) |
| KR (1) | KR101386697B1 (ru) |
| CN (2) | CN107496426A (ru) |
| BR (1) | BR112014032264A8 (ru) |
| CA (1) | CA2876926C (ru) |
| ES (1) | ES2668908T3 (ru) |
| MX (1) | MX365021B (ru) |
| RU (2) | RU2014151382A (ru) |
| WO (1) | WO2013191401A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101498973B1 (ko) | 2013-11-21 | 2015-03-05 | 현대모비스(주) | 차량용 주차 지원 시스템 및 방법 |
| GB201401005D0 (en) * | 2014-01-21 | 2014-03-05 | Ucl Business Plc | Inhibitor |
| KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB0201882D0 (en) | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| WO2003086178A2 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| UA84156C2 (ru) * | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний |
| AU2004268614C1 (en) * | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| GB0421438D0 (en) * | 2004-09-27 | 2004-10-27 | Astrazeneca Ab | Combination therapy |
| TWI393565B (zh) | 2004-06-04 | 2013-04-21 | Bioniche Life Sciences Inc | 甲磺酸伊馬替尼治療肝病變及病毒感染的用途 |
| CA2578956A1 (en) | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Combination comprising zd6474 and an imatinib |
| MX2007003506A (es) | 2004-09-27 | 2007-05-10 | Aztrazeneca Ab | Terapia de combinacion de cancer que comprende azd2171 e imatinib. |
| CA2580266A1 (en) * | 2004-10-08 | 2006-04-20 | Novartis Ag | Combination of organic compounds |
| CN101180060B (zh) | 2005-06-03 | 2011-12-28 | 诺瓦提斯公司 | 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合 |
| US20080003219A1 (en) | 2005-09-26 | 2008-01-03 | Minu, L.L.C. | Delivery of an ocular agent |
| EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| CA2667720A1 (en) | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| PT2305263E (pt) | 2007-06-07 | 2012-10-22 | Novartis Ag | Formas amorfas estabilizadas de mesilato de imatinib |
| TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| KR101138840B1 (ko) | 2009-12-28 | 2012-05-10 | 주식회사 셀트리온화학연구소 | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 |
-
2012
- 2012-06-18 KR KR1020120065193A patent/KR101386697B1/ko active Active
-
2013
- 2013-06-10 ES ES13807815.9T patent/ES2668908T3/es active Active
- 2013-06-10 CN CN201710777309.5A patent/CN107496426A/zh active Pending
- 2013-06-10 BR BR112014032264A patent/BR112014032264A8/pt not_active Application Discontinuation
- 2013-06-10 CA CA2876926A patent/CA2876926C/en active Active
- 2013-06-10 RU RU2014151382A patent/RU2014151382A/ru unknown
- 2013-06-10 RU RU2018128737A patent/RU2018128737A/ru unknown
- 2013-06-10 EP EP13807815.9A patent/EP2862573B1/en active Active
- 2013-06-10 CN CN201380032289.9A patent/CN104582704A/zh active Pending
- 2013-06-10 MX MX2014015785A patent/MX365021B/es active IP Right Grant
- 2013-06-10 US US14/409,441 patent/US9511068B2/en active Active
- 2013-06-10 WO PCT/KR2013/005068 patent/WO2013191401A1/ko not_active Ceased
- 2013-06-10 JP JP2015518325A patent/JP6030234B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107496426A (zh) | 2017-12-22 |
| WO2013191401A1 (ko) | 2013-12-27 |
| EP2862573A4 (en) | 2016-01-27 |
| RU2018128737A3 (ru) | 2019-03-14 |
| KR101386697B1 (ko) | 2014-04-18 |
| KR20130141998A (ko) | 2013-12-27 |
| BR112014032264A2 (pt) | 2017-06-27 |
| MX365021B (es) | 2019-05-20 |
| EP2862573A1 (en) | 2015-04-22 |
| ES2668908T3 (es) | 2018-05-23 |
| US9511068B2 (en) | 2016-12-06 |
| BR112014032264A8 (pt) | 2022-03-03 |
| US20150320750A1 (en) | 2015-11-12 |
| MX2014015785A (es) | 2015-06-10 |
| JP2015520226A (ja) | 2015-07-16 |
| JP6030234B2 (ja) | 2016-11-24 |
| CA2876926A1 (en) | 2013-12-27 |
| RU2014151382A (ru) | 2016-08-10 |
| EP2862573B1 (en) | 2018-03-07 |
| CA2876926C (en) | 2017-04-04 |
| CN104582704A (zh) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014078778A3 (en) | Antiviral azasugar-containing nucleosides | |
| JP2007519649A5 (ru) | ||
| RU2016121150A (ru) | Терапевтическое средство против заболеваний, связанных с гибелью клеток эндотелия роговицы, обусловленной состоянием эндоплазматического ретикулума | |
| WO2009080836A3 (en) | Macrocyclic indoles as hepatitis c virus inhibitors | |
| JP2011037901A5 (ru) | ||
| IL189032A (en) | Small compounds that correct incorrect folding of protein and their use | |
| JP2017504611A5 (ru) | ||
| JP2016535795A5 (ru) | ||
| JP2016505637A5 (ru) | ||
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| JP2013542261A5 (ru) | ||
| IL234262A (en) | Pharmaceuticals containing ccr3 inhibitors | |
| JP2009542581A5 (ru) | ||
| JP2013528563A5 (ru) | ||
| JP2013518914A5 (ru) | ||
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| JP2016020375A5 (ru) | ||
| RU2018128737A (ru) | Применение иматиниба или его фармацевтически приемлемой соли для лечения или предупреждения заболеваний, связанных с проницаемостью сосудов | |
| JP2012528824A5 (ru) | ||
| JP2010514733A5 (ru) | ||
| JP2016514688A5 (ru) | ||
| RU2016106641A (ru) | Терапевтические средства, направленные на ecm эндотелия роговицы | |
| NO20092764L (no) | Isosorbid mononitrat derivater for behandling av okular hypertensjon | |
| JP2014532063A5 (ru) | ||
| JP2008516959A5 (ru) |